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ABSTRACT 
Kevin Mensah-Biney 
The Effect of Exercise on the Antibody Response to Influenza Vaccine in Type 2 
Diabetics 
(Under the direction of Melinda Beck, Ph.D.) 
 
 Obesity is a growing health problem that is affecting over one third of the adult 
population in the United States. Obesity increases an individual’s risk for diseases such as 
hypertension, cardiovascular disease, and type 2 diabetes. The prevalence of type 2 
diabetes is growing in a trend similar to obesity in the United States. Obesity and type 2 
diabetes has been shown to be immunosuppressive and increase an individual’s 
susceptibility to influenza infection. Increased physical activity and exercise has been 
shown to decrease the risks for complications associated with obesity and type 2 diabetes 
as well as increasing immune function. In the present pilot study we wanted to look at the 
differences in antibody response between obese non-diabetics and obese diabetics based 
on exercise and physical activity. To do this we collected serum from obese non-diabetics 
and obese diabetics pre- and post-vaccination of the influenza vaccine and used an 
ELISA assay to determine the response of the four subclasses Immunoglobulin G 
antibodies to the influenza vaccine pre- and post-vaccination of influenza vaccine. We 
found that vaccination for influenza resulted in a significant change in IgG1 and IgG3 
serum titer. We found the amount of exercise did not result in significant changes in 
serum titer for any of the four IgG subclasses. Future studies should be conducted to 
determine defined relationship between exercise and immune response to influenza in 
obese and type 2 diabetics. 
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CHAPTER 1 
INTRODUCTION 
1.1 Obesity 
 Obesity is a health condition associated with excessive accumulation of adipose 
tissue. Obesity has become a growing health concern in the United States and around the 
world.  In the U.S., the percentage of obese individuals has dramatically increased in the 
past two decades to approximately 35.7% among the adult population.
1
 Obesity is 
typically caused by an individual’s behavioral choices such as eating high calorie diets 
and lacking physical activity. Obesity is related to many health problems since the 
condition increases one’s risks for diseases such as type 2 diabetes, hypertension, heart 
disease, etc. In addition to these conditions, obesity has been shown to weaken immune 
responses.
2
 
 There are many methods of determining whether an individual is obese such as 
measuring skinfold thickness, or waist circumference, and techniques such as bioelectric 
impedance and underwater weighing.
3
 The least expensive and most common way of 
determining obesity is by calculating an individual’s body mass index (BMI). BMI is 
calculated by dividing an individual’s weight in kilograms by their height squared in 
meters. According to the Centers for Disease Control and Prevention (CDC), an adult 
with a BMI lower than 18.5 is classified as underweight, an adult with a BMI between 
18.5 and 24.9 is classified as healthy weight, an adult with a BMI between 25.0 and 29.9 
is classified as overweight, and an adult with a BMI 30.0 and above is classified as obese. 
The main flaw with using BMI to determine obesity is that it correlates with body fat but 
does not actually measure the amount of body fat. Since muscle has a higher density than 
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adipose tissue, an individual with a high amount of muscle mass could have a high BMI 
despite having a low amount of body fat. 
1.2 Diabetes Mellitus 
 Approximately 11.3% of adults in the United States have diabetes.
4
 The disease is 
associated with high blood glucose levels known as hyperglycemia. Complications from 
hyperglycemia include heart disease, stroke, kidney disease, and neuropathy. The 
hyperglycemia can be attributed to problems with insulin, one of the hormones involved 
in regulating blood glucose. 
 Insulin is secreted by the beta cells in the pancreas when the levels of glucose in 
the blood are high such as after a meal. Insulin signals cells such as adipocytes, skeletal 
muscle cells, and heart muscle cells to transfer GLUT4 transporters to the cell membrane 
to take in more glucose and reduce the amount of glucose in the blood. Insulin also 
inhibits glucagon, a hormone that is secreted when blood glucose levels are low to result 
in more glucose being secreted in the blood. 
  There are two forms of diabetes, Type 1 and Type 2 diabetes. Type 1 diabetes is 
caused by an autoimmune attack of the beta cells of the pancreas and results in the body 
failing to produce insulin. Type 2 diabetes is associated with insulin resistance that comes 
from a disruption in the insulin signaling pathway. One of the risk factors for Type 2 
diabetes is being overweight or obese since it contributes to insulin resistance. Other risk 
factors include old age and genetics. Type 2 diabetes accounts for 90-95% of the 
diabetics in the United States.
5
 Type 2 diabetes can be treated or prevented from lifestyle 
choices such as a healthier diet or increased physical activity. Other treatments include 
bariatric surgery and drugs such as Metformin. 
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 Type 2 diabetes can be diagnosed by three different types of blood tests which 
include a fasting plasma glucose test, an oral glucose tolerance test, and measuring the 
levels of hemoglobin A1c. The fasting plasma glucose test involves testing the levels of 
glucose in the blood of an individual that has fasted in at least eight hours.
6
 A level below 
100 mg/dL is considered normal.
6
 An individual with a level between 100 and 125 mg/dL 
is classified as pre-diabetic and an individual with levels higher than 125 mg/dL is 
classified as diabetic.
6
 Pre-diabetics are individuals that have a higher than normal fasting 
blood glucose level but are not considered diabetic.
6
 The oral glucose tolerance test is 
similar to the fasting plasma glucose test but the individual drinks 75 grams of glucose 
dissolved in water after an eight hour fast and 2 hours before the test.
6
 The classifications 
for this test are pre-diabetics have a plasma glucose level between 140 and 199 mg/dL 
and diabetics have a level higher than 199 mg/dL.
6
 The hemoglobin A1c test does not 
involve fasting and represents blood glucose levels over the past three months.
6
 Glucose 
covalently binds to the protein hemoglobin in red blood cells to form hemoglobin A1c 
and red bloods cells have an average lifespan of three months. A level between 5.7 and 
6.4% is classified as pre-diabetic and a level higher than 6.4% is classified as diabetic.
6
 
1.3 Influenza Virus 
 The CDC estimates that between 5 to 20% of people in the U.S. get infected with 
influenza (flu) and more than 200,000 people are treated in the hospital for complications 
related to the flu.
7
 The spread of flu is typically at its peak during flu season which is 
between the fall and spring seasons in the U.S. Some common symptoms for the flu 
include fever, cough, sore throat, runny nose, muscle aches, headaches, and fatigue.
8
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Some individuals that are more vulnerable to the flu include older adults, children, 
pregnant women, and people with compromised immune systems.
8
 
 The flu is caused by infection with influenza virus. Individuals can spread the flu 
from approximately 6 feet away in droplets that come from talking, coughing, or 
sneezing.
9
 The viruses in these droplets can be inhaled into another person to infect their 
respiratory tract through the nose, throat, and lungs.
9
 Adults can infect others about a day 
before flu symptoms appear and symptoms can arrive one to four days after the virus 
enters a host.
9
 
 There are three different types of influenza viruses which are A, B, and C. 
Influenza A and B are the two types most associated with epidemics.
10
 The viral genome 
of Influenza A is composed of 8 RNA segments. Influenza A is classified into different 
subtypes based on two proteins on the viral surface known as hemagglutinin (H) and 
neuraminidase (N).
10
 There are 18 hemagglutinin subtypes that are classified from H1 to 
H18 and 11 neuraminidase subtypes that are classified from N1 to N11.
10
  
 Influenza viruses can change through processes known as antigenic drift and 
antigenic shift.
11
 In antigenic drift, there are mutations in the genome of the virus that can 
result in changes in the surface H protein such that antibodies do not recognize the altered 
H protein. In antigenic shift, a new viral strain forms from two different viral strains 
infecting a host cell and combining their segmented genetic material to form a new viral 
strain. 
1.4 Influenza Vaccine 
 The World Health Organization (WHO) recommends specific viral strains for 
inclusion in influenza vaccines and then individual countries make their own decisions 
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based on the recommendations. In the US, the Food and Drug Administration (FDA) 
determines the influenza strains that will be included in the vaccine. The vaccine contains 
the strains of viruses that are predicted to be the most common during the upcoming flu 
season. The vaccine typically is trivalent with three viral strains but for the 2013-2014 flu 
season, a quadrivalent vaccine with four viral strains was made available.
12
 The trivalent 
vaccine contains two Influenza A strains and one B strain while the quadrivalent vaccine 
contains two A strains and two B strains.
12
 Trivalent inactive vaccine (TIV) and live 
attenuated influenza vaccine (LAIV) are the two methods of vaccination.
12
 TIV is 
injected into the muscle and contains inactivated virus which is enriched in the H and N 
for antigen recognition. TIV is recommended for individuals older than 6 months.
12
 
LAIV is a nasal spray administered into the nostril and contains live and weakened viral 
strains. This type of vaccine is recommended for individuals between the ages of 2 and 
49.
12
 
1.5 Immunoglobulin G 
 The innate immune system and the adaptive immune system are the two major 
components of the immune system. The innate immune system protects the body from 
foreign agents with physical barriers such as skin, and mucosal membranes as well as 
phagocytic cells. The adaptive immune system relies on encountering a foreign antigen 
and developing a memory against that specific antigen to have a more rapid and powerful 
response to another infection of the antigen. The second exposure to a specific antigen is 
referred to as the secondary response. Vaccines are designed to generate this memory for 
the adaptive immune system to be protected from a possible infection. The lymphocytes 
types that are mainly involved in adaptive immunity are T and B cells.
15
 After the initial 
  
13 
 
encounter with an antigen, B cells differentiate into plasma cells that secrete antibodies 
that can bind to the antigen and prevent infection.
15
 
 Antibodies include IgG, IgM, IgD, and IgE. IgG is the most common antibody 
found in the blood.
15
 IgG antibodies are more active during a secondary response.
15
 IgG 
antibodies can be further classified into four different subclasses from IgG1 to IgG4. The 
number of the subclass correlates to each subclass’s relative abundance in the blood with 
IgG1 as the most abundant and IgG4 as the least abundant. IgG1 and IgG3 are more 
associated with reacting with viruses such as influenza.
15
 IgG2 is associated with reacting 
with pathogens with polysaccharide antigens such as bacteria like Streptococcus 
pneumonia.
15
 IgG4 is associated with repeated exposures to an antigen.
15
 
1.6 Obesity and Influenza Vaccination 
 Studies have shown that obesity is immunosuppressive and decreases the antibody 
response to tetanus toxoid and the hepatitis B vaccine.
2
 Diet-induced obese mice have a 
greater mortality to flu infection and weakened innate immune responses.
2
 An ongoing 
prospective observational study at the University of North Carolina Family Medicine 
Center examined the effect of BMI on the immune response to flu vaccine in human 
adults.
2
 Based on data from the first two years, it was determined that obese and healthy 
weight individuals increased their IgG antibodies specific for the vaccine one month after 
vaccination, However, one year after vaccination, the obese had a greater decline in 
antibody titers when compared with the healthy weight population.
2
 The decline in 
antibody titer in the obese from the study demonstrates that the obesity may have impair 
the immune response to the influenza vaccine. 
1.7 Diabetes, Obesity, and Exercise 
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 As highlighted in the previous section, the immunosuppressive nature of obesity 
can put obese individuals at a higher risk for infection and possibly reduce the 
effectiveness of vaccination. The immunity impairment may be due to leptin resistance, 
inflammation, metabolic changes, or other unknown mechanisms.
2
 Diabetes has also 
been shown to impair immunity. The impaired immunity can be due solely to diabetes or 
the common characteristics shared by diabetics such as old age and obesity. 
 Exercise and increased physical activity has been known as a behavioral change 
to treat and reverse the effects of obesity and diabetes. Exercise can decrease body fat and 
increase insulin sensitivity. Exercise has also been shown to reduce inflammation that can 
cause immunosuppression.
13
 The CDC recommends an equal mix of moderately intense 
to vigorous aerobic exercise per week and muscle strengthening exercise on 2 or more 
days a week for adults.
14
 
This project was designed to determine if there are differences in IgG subclass 
levels post influenza vaccination between obese individuals with and without diabetes 
who exercise compared with those who do not exercise. We hypothesized that exercising 
diabetics will have a greater response to influenza vaccination as compared to diabetics 
that do not exercise. 
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CHAPTER 2 
SPECIFIC AIMS AND HYPOTHESES 
Specific Aim One: To determine if vaccination for influenza increases the antibody titer 
for IgG1, IgG2, IgG3, and IgG4 in the study subjects. 
Hypothesis: The titer will increase for all four antibodies in all of the study subjects. 
Specific Aim Two: To determine if exercise exhibits a unique difference in antibody 
response to influenza vaccine in Type 2 diabetic subjects as compared to obese non-
diabetic subjects. 
Hypothesis: There will be a greater antibody response to influenza vaccine in high 
exercising diabetics than non-exercising diabetics. There will be similar results for the 
obese non-diabetic subjects. 
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CHAPTER 3 
METHODS 
3.1 Study Design: 
 The subjects in the study were taken from volunteers in an ongoing prospective 
observational study at the University of North Carolina Family Medicine Center which is 
an outpatient primary care facility located in Chapel Hill, NC. The larger study enrolled 
participants that were at least 18 years of age and were scheduled to receive the seasonal 
flu vaccine for the 2013-2014 flu season. All participants were excluded if they had the 
following criteria: immunosuppresion, self-reported use of immunomodulator or 
immunosuppressive drugs, acute febrile illness, history of hypersensitivity to any 
influenza vaccine components, history of Guillian-Barre syndrome, or use of theophylline 
preparations or Warfarin. 
 After enrollment, informed consent was obtained from all of the participants. The 
height and weight for all the participants were measured and a baseline blood sample was 
taken from each participants. The participants were then injected with one dose of the 
2013-2014 TIV (0.5 mL Fluzone (Sanofi Pasteur, Swiftwater, PA, USA) containing 
 A/California/7/2009 (H1N1)pdm09-like virus, A/Texas/50/2012 (H3N2) and 
B/Massachusetts/2/2012-like virus) in the deltoid muscle. All participants were given a 
Rapid Assessment of Physical Activity (RAPA) survey that they filled out at the center. 
Participants returned 28-35 days later to the center to obtain a post-vaccination blood 
sample. The serum from these blood samples were isolated and preserved as described 
below. 
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 In this study we selected serum samples from 107 participants. The participants 
were separated into six groups: non-exercising obese, non-exercising diabetics, 
inadequate exercising obese, inadequate exercising diabetics, high exercising obese, and 
high exercising diabetics. All of the participants reported their diabetes status orally after 
enrollment and were confirmed from their medical records. All of the obese participants 
in the study were participants that did not report diabetes (and confirmed from the 
medical record) and had a BMI classified as obese. The diabetic participants were 
participants that had reported having type 2 diabetes and had a BMI classified as obese. 
The high exercising obese category includes diabetics with a BMI that is classified as 
overweight to increase the sample size of the group. Exercise status was classified based 
on the participants’ response to the RAPA survey shown in Figure 1. Non-exercising 
participants were classified as such if they answered “no” to question 3 through question 
7, answered “yes” to either question 1 or question 2, and answered “no” to the question 
corresponding to “strength.” High exercising participants were classified as such if they 
met the CDC’s recommendation for physical activity which includes both activities to 
increase muscle strength and aerobic activity every week. To fit in this category, 
participants would have to answer “yes” for the question corresponding to “strength” and 
“yes” for either question 6 or question 7. Participants that did not fit into non-exercising 
or high exercising categories are classified in the inadequate exercising category. The 
individual that answered the survey in Figure 1 would be classified in the inadequate 
exercising group. 
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Figure 1. The RAPA survey given to all of the participants in the ongoing prospective 
observational study at the University of North Carolina Family Medicine Center to assess 
the amount of physical activity the participants conducted. 
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Table 1. Demographics of the study population 
Groups Number 
of 
Subjects 
Sex 
Ratio 
(M:F) 
Mean 
Age ± 
SD 
Age 
Range 
Race  Mean 
BMI ± 
SD 
BMI 
Range 
Non 
Exercising 
Obese 
15 3:12 56±9 41-69 9 white and 
6 black 
35.9±6 30.3-
49.6 
Non 
Exercising 
T2D 
18 8:10 57±10 32-70 11 white 
and seven 
black 
37.6±7 28.7-
54.2 
Inadequate 
Exercising 
Obese 
27 5:22 50±10 32-71 18 white 
and 9 black 
35.4±4 30.6-
41.9 
Inadequate 
Exercising 
T2D 
28 10:18 59±7 43-71 14 white, 
13 black, 1 
Asian 
38±7 30.0-
55.6 
High 
Exercising 
Obese 
9 3:06 57±12 33-71 5 white, 3 
black, 1 
Hispanic 
35±4 29.9-
42.1 
High 
Exercising 
T2D 
10 5:05 62±9 46-73 4 white and 
6 black 
32.5±5 26.6-
41.8 
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3.2 Serum Collection 
 Pre- and post-vaccine blood draws were collected into a vacutainer tube and 
allowed to clot for 30-60 minutes at room temperature and then refrigerated at 4°C. The 
blood was then centrifuged in the tubes at 800 xg for 10 minutes in a IEC Centra MP4R. 
After the centrifuge step, 0.5 mL of the serum was aliquoted into the small 1.2 mL serum 
tubes. These tubes were stored in a freezer at -80°C. 
3.3 Enzyme-Linked Immunosorbent Assay (ELISA) 
 To quantify the four different IgG antibodies, ELISA was used with the 2013-
2014 seasonal TIV as the antigen. The vaccine was diluted in a carbonate coating buffer 
to be absorbed in 96-well microtitration ELISA plates. Four different ELISA plates were 
used for the four different antibodies. For three of the plates that would quantify IgG1, 
IgG2, and IgG3, the vaccine was diluted in a 1:160 ratio in the coating buffer. For the 
fourth plate that would quantify IgG4, the vaccine was diluted in a 1:80 in the coating 
buffer. All of the plates were filled with 50 μL of the diluted vaccine solution in each 
well. The plates were refrigerated overnight at 4°C. 
 After refrigeration, the plates were discarded of the vaccine solution and the wells 
were filled with 200 μL of block buffer to block the remaining protein-binding sites in the 
well. The block buffer was composed of coating buffer and 3% of nonfat dry milk. The 
plates were then incubated in 37°C for at least one hour.  
 The next step involved thawing the serum samples and diluting in dilution buffer. 
The dilution buffer was composed of PBS solution and 3% nonfat dry milk. Fifteen pre- 
and post-vaccination serum samples were used for each four plate set. An internal control 
sera and a blank sample were included in each set. The blank sample did not contain any 
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serum. Each thawed serum samples were individually diluted into four different 
solutions. One solution had the serum diluted in a 1:6400 ratio, another solution had the 
serum diluted in a 1:100 ratio, another solution had the serum diluted in a 1:400 ratio, and 
the last solution had the serum diluted in a 1:200 ratio.  
 After the incubation, the plates were washed three times with PBSt solution using 
an ELISA plate washer. All of the plates were filled with 50 μL triplicates of each 
sample. The IgG1 plate was filled with the 1:6400 dilution solution, the IgG2 plate was 
filled with the 1:100 dilution solution, the IgG3 plate was filled with the 1:400 dilution 
solution, and the IgG4 plate was filled with the 1:200 dilution solution. The plates were 
then incubated in 37°C for 2 hours. The antibodies in the serum would react and bind to 
the vaccine antigen in the wells. 
 The next step involved detecting the bound antibodies with a corresponding 
horseradish peroxidase-conjugated goat anti-human IgG subtype (Abcam, Cambridge, 
MA, USA). Anti-human IgG1, IgG2, and IgG3 were diluted in dilution buffer in a 1:1000 
ratio. Anti-human IgG4 was diluted in dilution buffer in a 1:500 ratio. After the 
incubation, the plates were washed three times with PBSt using the ELISA plate washer. 
The anti-human IgG solutions were added to the plate corresponding to specific antibody 
subtype. Each well was added with 50 μL of the solution. The plates were incubated in 
37°C for 1 hour. 
 After the incubation, the plates were washed three times with PBSt using the 
ELISA plate washer. Immediately after the plate washing, every well was filled with 100 
μL of TMB substrate solution mix which was composed of an equal mix of TMB 
solution and peroxide solution. The addition of the TMB substrate solution would form a 
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blue solution of varying intensities based on the samples. The plates were incubated at 
room temperature for 30 minutes. The wells were then added with 100 μL of 2M sulfuric 
acid to stop the reaction with the TMB substrate solution and turn the blue solution into a 
yellow solution. The color intensity of each well was measured by absorbance at 450 nm 
using an ELISA plate reader. The color intensity would correspond with the antibody titer 
in the well. 
3.4 Statistical Analysis: 
 The ELISA data was assessed using GraphPad Prism®. Differences in antibody 
titer were assessed using the ANOVA test. A p-value <0.05 was considered significant.   
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CHAPTER 4 
RESULTS 
4.1 Demographics of the Study Population 
 The participants in the study were classified into six groups: non-exercising 
obese, non-exercising type 2 diabetics, inadequate exercising obese, inadequate 
exercising type 2 diabetics, high exercising obese, and high exercising type 2 diabetics. 
The demographics of the participants are listed in Table 1. 
4.2 Antibody Response 
 For IgG1, there was a significant change in antibody titer for all groups from pre- 
to post-vaccination with influenza vaccine. There was not a significant change in 
antibody titer based on the different groups. Among the obese, higher exercise correlated 
with increased expression of IgG1 after vaccination. For the non-exercising obese, 24% ± 
70 was the percent change. In the inadequate exercising obese, there was a 30% ± 40 
percent change, while the percent change was 35% ± 30 among the high exercising 
obese. The percentage of obese with at least a 30% percent change in IgG1 among the 
non-exercising, inadequate exercising, and high exercising were 53%, 57%, and 50% 
respectively showing no clear trend (Figure 7). Between non-exercising and high 
exercising diabetics, exercise correlated with a higher expression of IgG1 with the 
percent change being 21% ± 60 and 40% ± 60 for the respective groups. However, 
inadequate exercising diabetics showed a -7.1% ± 60 percent change in IgG1 antibody 
titer from pre- to post-vaccination. The percentage of diabetics with at least a 30% 
percent change in IgG1 among the non-exercising, inadequate exercising, and high 
exercising were 65%, 26%, and 57% respectively showing no clear trend (Figure 7). 
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Figure 2. The mean percent change in IgG1 antibody titer from pre- to post-vaccination 
among the different groups. 
 There were not any significant changes in IgG2 expression between the groups 
and from pre- to post-vaccination in all of the groups. For non-exercising obese, there 
was a -15% ± 80 percent change in IgG2 from pre- to post-vaccination. From inadequate 
exercising obese showed a 2.4% ± 40 percent change while high exercising obese showed 
a -32% ± 100 decrease. The percentage of obese with at least a 30% percent change in 
IgG2 among the non-exercising, inadequate exercising, and high exercising were 42%, 
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32%, and 17% respectively showing a decreasing trend (Figure 7). In non-exercising 
diabetics, there was a 12% ± 40 percent change in IgG2 expression. In inadequate 
exercising diabetics, there was a slight decrease in expression to 6.7% ± 120 and while in 
high exercising diabetics, the expression was 9.3 ± 30 percent change. The percentage of 
diabetics with at least a 30% percent change in IgG2 among the non-exercising, 
inadequate exercising, and high exercising were 30%, 22%, and 14% respectively 
showing a decreasing trend (Figure 7) 
 
. 
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Figure 3. The mean percent change in IgG2 antibody titer from pre- to post-vaccination 
among the different groups. 
 For IgG3, there was a significant change in antibody expression in all groups from 
pre- to post-vaccination. The difference in expression between the groups was not 
significant. For the obese, exercise slightly correlated with a decreases in IgG3 
expression. The percentage of obese with at least a 30% percent change in IgG3 among 
the non-exercising, inadequate exercising, and high exercising were 64%, 30%, and 50% 
respectively showing no clear trend (Figure 7). In the non-exercising obese category, 
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there was a 31% ± 50 percent change from pre- to post-vaccination. From inadequate 
exercising to high exercising diabetics, there was a 27% ± 40 percent change and an 18% 
± 27 percent change respectively. The percentage of diabetics with at least a 30% percent 
change in IgG3 among the non-exercising, inadequate exercising, and high exercising 
were 55%, 45%, and 50% respectively showing no clear trend (Figure 7). 
 
Figure 4. The mean percent change in IgG3 antibody titer from pre- to post-vaccination 
among the different groups. 
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 For IgG4, there were not any significant differences between the groups and 
significant changes from vaccine treatment in all of the groups. For non-exercising obese, 
there was a -38% ± 60 percent change in IgG4 expression from pre- to post-vaccination. 
From inadequate exercising to high exercising obese, there was a slight increase from 
9.0% ± 40 to 14% ± 40 respectively. The percentage of obese with at least a 30% percent 
change in IgG4 among the non-exercising, inadequate exercising, and high exercising 
were 8.3%, 36%, and 43% respectively showing an increasing trend (Figure 7). In non-
exercising diabetics, there was a -46% ± 200 percent change in expression. In inadequate 
exercising diabetics, there was a -47% ± 80 percent change. In high exercising diabetics, 
the expression increased 7.7% ± 30 fold. The percentage of diabetics with at least a 30% 
percent change in IgG4 among the non-exercising, inadequate exercising, and high 
exercising were 19%, 13%, and 29% respectively showing no clear trend (Figure 7). 
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Figure 5. The mean percent change in IgG4 antibody titer from pre- to post-vaccination 
among the different groups. 
 All of the groups had varying changes in the different IgG antibodies from pre- to 
post-vaccination for flu. In the non-exercising obese group, there was a 24% percent 
change in IgG1, a -15% percent change in IgG2, a 31% percent change in IgG3, and -
38% percent change in IgG4. In the non-exercising diabetic group, there was a 21% 
percent change in IgG1, a 12% percent change in IgG2, a -18% percent change in IgG3, 
and a -46% decrease in IgG4. In the inadequate exercising obese group, there was a 30% 
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percent change in IgG1, a 2.4% percent change in IgG2, a 27% percent change in IgG3, 
and a 9.0% percent change in IgG4. In the inadequate exercising diabetic group, there 
was a -7.1% percent change in IgG1, a 6.7% percent change in IgG2, a 26% percent 
change in IgG3, and a -47% percent change in IgG4. In the high exercising obese group, 
there was a 35% percent change in IgG1, a -32% percent change in IgG2, an 18% percent 
change in IgG3, and a 14% percent change in IgG4. In the high exercising diabetic group, 
there was a 40% percent change in IgG1, a 9.3% percent change in IgG2, a -36% percent 
change in IgG3, and a 7.7% percent change in IgG4. 
 
  
  
Figure 6. Vaccine treatment induced significant expression in IgG1 and IgG3, but not in 
IgG2 and IgG4. 
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Figure 7. The percentage of each group that had a least a 30% percent change four each 
of the antibodies. 
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CHAPTER 5 
DISCUSSION 
5.1 Immune Response to the Influenza Virus 
 Vaccination has been recommended as the most effective protection against 
influenza infection. Obesity and diabetes are immunosuppressive conditions so it is 
important for individuals with these conditions to be vaccinated to better protect 
themselves from the flu. It is important to measure how individuals with these conditions 
respond to the flu vaccine to determine if they are potentially protected from flu 
infection. In this study, we observed obese individuals that are either diabetic or non-
diabetic and measured their differences in antibody response to influenza vaccination 
based on their level of exercise. We hypothesized that the participants that did the higher 
amounts of exercise would have an increased expression of all four IgG antibody 
subclasses after vaccination for the flu. The study came up with some unexpected results. 
 IgG1 antibodies react with viral antigens so it is expected that vaccine treatment 
would result in increased expression. The trend was seen in all groups except the 
inadequate exercising diabetic group. More exercise correlated with an increase in IgG1 
expression in the obese suggesting that exercise can help immune response for the obese. 
The same trend was seen between non-exercising and high exercising diabetics similar to 
the obese which would suggest that exercise improves immune response in diabetics in 
the same way as obesity. 
  Exercise shows an increasing trend in IgG2 expression in the obese. In diabetics, 
exercise does not show a clear trend. The lack of trend could be due to IgG2 antibodies 
are associated more with bacterial antigens rather than viral antigens such as the flu. 
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 For IgG3 antibodies, exercise correlates with decreased percentage changes in 
expression after vaccination in the obese. For diabetics, exercise does not show a clear 
trend in IgG3 expression. For all groups except non-exercising diabetics and high 
exercising diabetics, there was an increase in antibody expression for IgG3. The increase 
in expression is expected since IgG3 is another antibody associated with viral antigens 
such as the flu. 
 For the obese, exercise shows a slight increasing trend in IgG4 antibody 
expression. In the diabetic groups, exercise does not show trend in antibody expression. 
This could be due to IgG4 not being associated with viral antigens. 
5.2 Limitations 
 This study had several limitations. One limitation was the use of ELISA for 
determining immune response. The use of ELISA is a limitation because the technique 
shows the amount of antibodies binding to the vaccine antigens but does not actually 
show where the antibodies bind to the virus and whether such binding would actually 
hinder viral activity. Another limitation was that diabetes was based on a previous 
medical diagnosis and we did not know the time of diagnosis meaning that individuals 
that were diagnosed with diabetes may no longer be considered diabetics by the time of 
the study. Not knowing the time of diagnosis also means that results could be different 
for diabetics that were diagnosed recently or diagnosed many years ago. Another 
limitation is that we did not determine specific types of medications that individuals 
could be taking at the time. Individuals could be taking medications that hinder or 
improve immunity and thus alter the antibody response due to the medications. Another 
limitation is that individuals were separated into exercise categories based on their results 
  
34 
 
on a survey meaning that their responses on the survey may not actually reflect actual 
exercise habits. 
5.3 Future Studies 
 Future studies could separate the inadequate exercising groups into more groups 
that reflect exercise habits such as aerobic exercise or muscle strengthening exercise to 
observe whether the type of exercise for individuals that do not meet the CDC’s 
requirement for exercise can have a different effect on antibody expression. Another 
study can include more subjects to increase statistical power. Future studies could also 
include healthy weight and overweight individuals to see if all individuals experience 
differences in antibody expression. Future studies can look at type 1 diabetes to see if 
there are different results between type 1 and type 2 diabetes. Future studies can examine 
other aspects of the adaptive immunity outside of the antibodies such as T cell and 
cytokine expression. 
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